CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology)

N/A

Report date: 2025/05/06 20:00:08

Base Information

Drug NameCD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsInterleukin-3 receptor subunit alpha modulatorsC-Type lectin domain family 12 member A modulators

TargetsMyeloid cell surface antigen CD33Interleukin-3 receptor subunit alphaC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid

Inactive IndicationsN/A

Other Information

ATC CodeN/A